Abstract Library

#1245 Identification of Response Predictors to Temozolomide-Based Chemotherapy

Introduction: Capecitabine and temozolomide are active in the treatment of metastatic pNETs, with response rates ranging from 30% to 70%. Several small retrospective series have suggested that MGMT deficiency may predict response to temozolomide, however expression of MGMT has not been validated as a predictive biomarker. Cytotoxic chemotherapy is thought to be most active in aggressive tumors, however the ki-67 index has not been formally evaluated as a predictive factor. It is unclear whether chromosomal instability (which correlates with alternate lengthening of telomeres) predicts response.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Strosberg J

Authors: Strosberg J, Cives M, Brelsford M, Black M, Meeker A,

Keywords: ki67, MGMT, ALT, chromosomal instability, temozolomide, capecitabine, pNET,